Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind multicenter study of LDR2402 injection in Chinese adults with mild to moderate primary hypertension
CTR20253348Phase 2Active
- Sponsor
- Xianyan Biotech
- Start
- Sep 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LDR2402 in essential hypertension (2 arms), sponsored by Xianyan Biotech. Started Sep 2025; status: active.
02
Drugs
LDR2402
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20253348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253348.